文献速递外周动脉疾病

性别特异性获益:TEG-PM指导下的外周动脉疾病血栓预防

Sex-specific benefits of thromboelastography-guided thromboprophylaxis in peripheral artery disease.
PubMed 文献 · J Vasc Surg · 2026-03-06

该前瞻性队列研究纳入443例下肢血运重建患者,比较TEG-PM指导抗血小板治疗与标准经验性双联抗血小板治疗的性别差异。

要点

  • TEG指导治疗总体降低血栓事件(5.4% vs 19.3%,HR 0.312)。

核心结论

  • TEG-PM指导的血栓预防对外周血运重建后女性的大截肢保护优于男性。
  • 女性87%相对风险降低、需治疗人数7,具有临床意义。

研究设计与样本

  • 前瞻性队列研究,纳入443例在马萨诸塞总医院(2020-2025)接受下肢血运重建的连续患者。
  • TEG-PM指导组147例(女46,男101),标准经验性双联抗血小板组296例(女102,男194)。
  • 术前及术后1、3、6个月行TEG-PM检测并调整抗血小板治疗,随访至12个月。

主要发现

  • 女性TEG指导组无截肢生存优于男性(事件8.7% vs 22.8%;62% RRR)。

关键数值与推荐

  • 主要结局为12个月大截肢(踝以上)。
  • 次要结局包括血栓事件、全因死亡和无截肢生存。
  • 亚组分析显示女性在糖尿病、慢性肾病和慢性肢体威胁性缺血等高危人群中获益一致。

临床怎么用

  • 对下肢血运重建患者,尤其女性,可考虑常规TEG-PM监测以指导抗血小板治疗。
  • 精准医学抗血小板策略可能有助于缩小外周动脉疾病性别结局差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate sex-specific differences in clinical outcomes after thromboelastography with platelet mapping (TEG-PM)-guided antiplatelet therapy compared with standard empiric dual antiplatelet therapy in patients undergoing peripheral artery disease revascularization. METHODS: This prospective cohort study enrolled 443 consecutive patients undergoing lower extremity revascularization at Massachusetts General Hospital (2020-2025). Patients received either TEG-PM-guided antiplatelet adjustment (n = 147; 46 female, 101 male) or standard empiric dual antiplatelet therapy (n = 296; 102 female, 194 male). TEG-PM testing was performed preoperatively and at serial intervals post procedure (1, 3, and 6 months), with antiplatelet therapy adjusted accordingly. Clinical outcomes were followed through 12 months. The primary outcome was major amputation (above-ankle) at 12 months. Secondary outcomes included thrombotic events, all-cause mortality, and amputation-free survival. Sex-stratified analyses and treatment × sex interaction testing were performed. RESULTS: Women receiving TEG-guided therapy demonstrated significantly lower major amputation rates compared with men within the same treatment arm (2.2% vs 16.8%; P = .013; odds ratio, 0.110; 95% confidence interval, 0.014-0.852), representing an 87% relative risk reduction with a number needed to treat of 7. In contrast, no significant sex difference was observed in the standard care arm (18.6% vs 21.1%; P = .614). The treatment × sex interaction approached statistical significance (odds ratio, 0.129; P = .060), suggesting differential treatment response by sex. Women in the TEG-guided arm also demonstrated superior amputation-free survival compared with men (8.7% vs 22.8% events; 62% RRR). TEG-guided therapy reduced thrombotic events overall (5.4% vs 19.3%; log-rank P < .001; hazard ratio, 0.312; 95% confidence interval, 0.156-0.624), with a similar benefit observed in both sexes. Subgroup analyses demonstrated consistent female benefit across high-risk populations, including patients with diabetes, chronic kidney disease, and chronic limb-threatening ischemia. CONCLUSIONS: TEG-PM-guided thromboprophylaxis appears to provide greater protection against major amputation in women compared with men after peripheral revascularization. The 87% relative risk reduction in amputation observed in women, with a number needed to treat of 7, represents a clinically meaningful benefit. These findings suggest that a precision medicine approach to antiplatelet therapy may help to address the historical outcomes gap between women and men with peripheral artery disease. Routine TEG-PM monitoring should be considered, particularly in female patients undergoing lower extremity revascularization.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cieri IF, Alvarez AR, Nurko A, et al. Sex-specific benefits of thromboelastography-guided thromboprophylaxis in peripheral artery disease. J Vasc Surg. 2026. PMID: 41794192. doi:10.1016/j.jvs.2026.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。